ANIP vs NKTX
ANIP: A diversified biopharmaceutical company focused on growing its Rare Disease, Brands, and Generics segments through a combination of internal development and strategic acquisitions. NKTX: Nkarta is a clinical-stage biotech developing off-the-shelf, engineered natural killer (NK) cell therapies aimed at treating autoimmune diseases through targeted B-cell depletion.
Side-by-side fundamentals
| Metric | ANIP | NKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $78.37 | $2.26 | |
| Market cap as of 2026-08-01 | $1.9B | $162M | |
| P/E as of 2026-08-01 | 19.65 | n/a | |
| PEG as of 2026-08-01 | 1.13 | n/a | |
| Net margin as of 2026-08-01 | +10.0% | -17566.7% | ANIP higher |
| Gross margin as of 2026-08-01 | +60.8% | n/a | |
| Operating margin as of 2026-08-01 | +13.4% | -19250.0% | ANIP higher |
| ROE as of 2026-08-01 | +17.8% | -30.9% | ANIP higher |
| ROA as of 2026-08-01 | +6.6% | -24.2% | ANIP higher |
| Debt / equity as of 2026-08-01 | 1.09 | 0.00 | NKTX lower |
| Revenue growth (YoY) as of 2026-08-01 | +37.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +40.8% | n/a | |
| Dividend yield as of 2026-08-01 | +0.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-08-01 | 0.47 | 0.94 | |
| 1-year return as of 2026-07-27 close | +16.1% | +4.6% | ANIP higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.